Sai Parenteral'sQ4 FY26
Sai Parenteral's Q4 FY26 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹528P/E: 115.1Market Cap: ₹2.4K CrSector: Pharmaceuticals & Biotechnology
Management growth scorecard
Revenue
N/A
Margin
N/A
Fundraise
N/A
Order
N/A
Capex
N/A
0 of 0 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
- →FY '27 revenue guidance is INR 750 crores, reflecting a conservative estimate due to typical H1-H2 seasonality (40%-60% split).
- →FY '27 targets 17% EBITDA margin, up from ~14.6% in Q4 FY '26, driven by vertical integration and manufacturing shifts.
- →Full operationalization of ongoing INR 440 crores capex projects expected by end of FY '27, with revenue impact beginning FY '28.
- →FY '28 anticipated as a ramp-up year with contributions from new Australian facility, expanded capacities, EU-GMP upgrades, and R&D center.
- →Long-term growth supported by over 50% revenue from long-term CDs contracts in regulated markets.
- →67 dossiers under development at Sai to be commercialized in FY '27 and FY '28, enhancing future sales visibility.
- →Vertical integration with Noumed to boost manufacturing margins and stabilized profitability.
- →Shift to global IP-led platform accelerating product launches from 18-24 months to 6-9 months.
Margin guidance
- →FY 27 is an execution year with a targeted revenue of INR 750 crores and EBITDA margin of 17%.
- →Full impact of investments expected in FY 28, with operational Australian facility, expanded capacities, EU-GMP compliant infrastructure, and dedicated R&D center contributing to revenue and margin expansion.
- →Transition from asset-building to monetization phase; operating leverage, vertical integration, and IP monetization expected to drive growth and profitability.
- →Consolidated revenues grew 133% in FY 26; EBITDA up 18%, reflecting strong growth momentum.
- →Long-term CDMO contracts and integration of Noumed to provide stability and growth in earnings and EPS.
- →Working capital efficiency expected to improve with increased CDMO exports.
- →Management expresses confidence in meeting market expectations and sustaining profitable growth trajectory.
3 more insights locked — sign up free to unlock
Fundraise plans
- →For FY '27, Sai Parenterals does not indicate any new fundraising through equity or debt; the focus is on executing ongoing capex programs.
- →The INR440 crores growth capex program is funded through IPO proceeds, internal accruals, and existing debt facilities.
- →The Australian expansion capex (AUD 53 million / INR311 crores) is partly funded by a federal government grant (AUD 20 million) with the balance through a combination of internal accruals and debt.
- →Peak debt is expected in FY '27, with a comfortable debt-to-equity ratio of 0.6 times; debt levels are expected to decline from FY '28 onwards.
- →Working capital requirements for incremental revenue growth (~25-30%) will primarily be funded via internal accruals and moderate additional debt.
- →No explicit mention of fresh equity fundraising beyond IPO proceeds was made for upcoming periods.
Order book
The transcript provided does not explicitly mention the current or expected order book or pending orders of Sai Parenterals Limited. However, several points related to growth and business outlook can be inferred:
- Sai Parenterals has secured new long-term CDMO export contracts, indicating a healthy pipeline of orders.
- The company emphasizes strong visibility for future growth through 67 dossiers under development, expected to be commercialized in FY27 and FY28.
- The vertical integration with Noumed and expansion of facilities are expected to improve manufacturing capacity and support increased order fulfillment.
- Long-term supply agreements and customer relationships, especially in regulated markets, suggest a stable and growing order book.
- FY27 guidance targets INR 750 crores revenue based on organic growth and integration, implying a robust pending orders backlog to meet this forecast.
No explicit numeric order book values or pending order details are disclosed in the transcript.
Capex plans
- →Sai Parenterals is executing a INR440 crores growth capex program focused on capacity expansion and upgradation in India and Australia, plus a new dedicated R&D center.
- →INR110 crores capex in India for capacity expansion and EU-GMP upgrades at manufacturing facilities, fully funded by IPO proceeds.
- →INR15 crores investment towards establishing the R&D center in India, also funded through IPO proceeds.
- →Australian entity Noumed facility expansion involves a total planned capex of AUD 53 million (INR311 crores), with AUD 20 million grant from the Australian government.
- →AUD 40 million invested so far in the Australian project, funded through a mix of debt and internal accruals.
- →All major capex projects expected to be completed by FY 2027 (Q4), with no revenue contribution expected in FY 27.
- →Full impact of these investments will start reflecting in FY 28 and beyond, driving revenue, margin expansion, and profitability.
How does Sai Parenteral's rank vs peers in Pharmaceuticals & Biotechnology?
Pro feature1Sai Parenteral's
See full Pharmaceuticals & Biotechnology sector rankings
How does Sai Parenteral's rank in Pharmaceuticals & Biotechnology?
Compare Sai Parenteral's against every Pharmaceuticals & Biotechnology company (Q4 FY26) on revenue, margins and earnings-call signals.